Key result
Serotonin transporter inhibitors, dichloroacetate, and simvastatin appear to prevent and reduce pulmonary arterial medial hyperplasia through anti-proliferative and pro-apoptotic effects.
Serotonin transporter inhibitors, dichloroacetate, and simvastatin represent promising novel therapeutic avenues for pulmonary arterial hypertension by targeting vascular remodelling.
Hypothesis-generating for PAH remodeling therapies; leaves open clinical translation pending trials.
Pulmonary arterial hypertension (PAH) is a devastating disorder characterized by abnormal increased vasoconstriction and vascular remodelling. In this review we discuss the pathophysiology, genetic basis and clinical features of this disorder. Current therapy of PAH is based on an understanding of its pathogenesis, and we review current treatment options based on the pathophysiology of the disease. We discuss three promising novel therapies studied in animal models and human tissue. All three therapies appear to prevent and reduce pulmonary arterial medial hyperplasia through their anti-proliferative and/or pro-apoptotic effects: serotonin transporter inhibitors by blocking serotonin uptake; dichloroacetate by activating voltage-gated potassium channels; and simvastatin by preventing activation of small GTPases.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2006) conducted a review in Pulmonary arterial hypertension. Serotonin transporter inhibitors, dichloroacetate, and simvastatin was evaluated. Serotonin transporter inhibitors, dichloroacetate, and simvastatin appear to prevent and reduce pulmonary arterial medial hyperplasia through anti-proliferative and pro-apoptotic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: